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Abstract 
Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for 
blood cell sampling for quantification of breakpoint cluster region-Abelson oncogene (BCR-ABL) 
transcript levels to monitor treatment responses in chronic myeloid leukemia (CML) patients.   
Methods: Peripheral blood samples were collected from 20 healthy individuals and 165 CML patients at 
various stages of treatment response. Level of BCR-ABL mutation gene transcripts were determined by 
RNA extraction and quantitative real time polymerase chain reaction (RT-PCR). 
Results: The ratio of BCR-ABL transcripts/ABL transcripts in blood cells was significantly higher (p < 
0.05) than in plasma for untreated and treated patients. Patients who received tyrosine kinase inhibitor 
(TKI) therapy and achieved major molecular response during treatment had the lowest mean ratio 
detected in blood cells (0.06 ± 0.0 %) and the ratio was below the detectable limit in plasma samples. 
Unlike plasma samples, BCR-ABL/ABL transcript ratios in blood cell samples strongly correlated with 
white cell counts in CML patients undergoing all types of treatment responses.   
Conclusion: Blood cell sampling is more sensitive than plasma sampling in diagnosis and evaluation of 
CML treatment response.  
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Chronic myeloid leukemia (CML) is a proliferative 
clonal disorder that occurs due to reciprocal 
translocation between chromosome 9 and 
chromosome 22 and forms the “Philadelphia 
Chromosome” (PC). The fusion gene, breakpoint 
cluster region-Abelson oncogene (BCR-ABL), is 
formed as a result of reciprocal translocation of 
ABL gene from chromosome 9 onto the BCR 
gene on chromosome 22 [1]. BCL-ABL gene 
causes dysregulated tyrosine kinase activity and 
consequently results in uncontrolled malignant 
BCR-ABL cell proliferation and cell resistance to 
apoptosis [2].  
 
Prior to the introduction of tyrosine kinase 
inhibitors (TKIs), the main drugs used to treat 
Ting et al 
Trop J Pharm Res, March 2017; 16(3): 658  
 
CML were busulphan, hydroxyurea and 
interferon-alpha, which do not selectively target 
BCR-ABL cells. The various types of adverse 
reactions caused by these non-targeted 
molecular drugs have led to their replacement 
with TKI therapy. TKI drugs, such as imatinib 
mesylate, are targeted molecular therapies used 
to treat CML. TKI therapy induces BCR-ABL cell 
death through various mechanisms, which 
include necrosis-like cell death mediated by 
Omi/HtrA2 intermembrane protein; 
downregulation of the level of antiapoptotic 
proteins XIAP, cIAP1, and Bcl-x(L); caspase-
independent apoptosis; and programmed cell 
death [3]. Tyrosine kinase inhibitors have 
dramatically improved the life span and the 
quality of life of CML patients.  
 
The discovery of PC in CML patients in the 
1960s promoted the use of molecular cytogenetic 
as an important tool for diagnosing CML. The 
development of fluorescent in situ hybridization 
technique in addition to cytogenetic analysis 
enabled high-resolution methods to detect the 
PC fusion signal pattern for assessing complete 
cytogenetic response. Advanced real-time 
polymerase chain reaction was eventually 
applied for quantification of BCR-ABL transcripts 
and was found to be feasible for minimal residual 
disease monitoring in CML patients [4].  
 
In current practice, peripheral blood cells have 
largely replaced the use of bone marrow cells for 
gene expression testing to monitor treatment 
response and detecting disease relapse among 
CML patients. The use of peripheral blood for 
analysis is preferred over bone marrow sampling 
as it is a minimally invasive and simpler 
procedure. A drawback of using peripheral blood 
comes from the low white blood cell count among 
patients receiving TKI, which may result in poor 
RNA quality and consequently give false low 
BCR-ABL transcript concentrations, especially in 
patients who have achieved major molecular 
response [5].  
 
Numerous studies indicate that nucleic acids in 
plasma could serve as useful biomolecules for 
diagnosing cancer as well as for evaluating the 
efficacy of treatment [6]. The mechanism and 
origin of plasma nucleic acids have yet to be 
completely discovered; however, administration 
of anticancer drugs has been shown to be 
strongly associated with cancer cell death and 
release of nucleic acids into plasma [7], leading 
to the suggestion of using plasma nucleic acids 
for routine cancer diagnostic work.  
 
Molecular diagnostic tests conducted on nucleic 
acids in plasma samples are not only confined to 
patients with solid localized tumors, but also 
those with hematological malignancies such as 
chronic lymphocytic leukemia and 
myeloproliferative disease [8].  
 
Therefore, the diagnostic value of plasma RNA 
for quantification of BCR-ABL transcripts was 
evaluated in this study.  We quantified BCR-ABL 
transcript levels in blood cell RNA samples and 
plasma RNA samples of CML patients at various 
stages of treatment response and compared their 





Study subjects  
 
This research was conducted in accordance with 
the International Ethical Guidelines for 
Biomedical Research Involving Human Subjects 
[9]. The protocol was reviewed and approved by 
the Medical Review & Ethics Committee 
(MREC), Ministry of Health Malaysia (NMRR ID: 
NMRR-10-645-5895).  This study was a 
prospective study of CML adult patients seen at 
the Hematology Clinic of Ampang Hospital, the 
national referral center for hematological 
malignancies in Malaysia. A total of 165 CML 
patients comprised of both genders, three main 
races in Malaysia, and spanning all adult ages 
were recruited through voluntary participation.  
 
CML patients on anticancer drugs other than 
TKIs were excluded from this study. Control 
blood samples were obtained from 20 healthy 
blood donors from the National Blood Bank, 
Kuala Lumpur, Malaysia. All CML patients and 
healthy individuals provided written informed 
consent for use of their samples in this research. 
Patient information, such as age, ethnicity, drug 
regimen, disease status, treatment duration and 
treatment response, was collected by 
retrospective review of clinical case notes. The 
disease status of CML patients was categorized 
according to the European Leukemia Net [10].  
 
RNA extraction procedure, 
 
Peripheral blood samples of study subjects were 
collected in ethylenediaminetetraacetate (EDTA) 
tubes. Plasma was separated from blood cells by 
centrifugation at 1200 x g for 10 minutes. RNA 
was extracted from approximately 7 × 106 cells; 
and a volume of 2 mL of plasma fraction was 
aliquoted for plasma RNA extraction.   RNA 
extraction of blood cell and plasma samples was 
conducted as described in a previous study [11].  
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Determination of RNA sample quality and 
quantity 
 
RNA sample quality (A260/280) and purity and 
(A260/230), as well as RNA concentration were 
determined using a Nanodrop spectrophotometer 
(Thermo Scientific). RNA samples were stored at 
-80 ˚C for BCR-ABL gene quantification. 
 
Quantification of BCR-ABL to ABL ratio using 
real time-polymerase chain reaction 
 
RT-PCR experiments were carried out on a 
Rotor-Gene 6000 instrument and the Rotor-Gene 
Q series software (Qiagen) was used for 
analyzing the quantification of BCR-ABL gene 
and ABL gene expression. PCR was performed 
using Molecular MD’s One-step qRT-PCR BCR-
ABL kit (Portland, OR, USA).The target gene 
was BCR-ABL whereas ABL was used as 
reference gene. The technique was based on the 
TaqMan® MGB® probe technology. Paired 
plasma and cell samples were analyzed 
concurrently on the system.   Gene specific 
primers, probes, and internal quality controls 
were provided in the Molecular MD’s One-step 
qRT-PCR BCR-ABL kit (Portland, OR, USA).  
 
PCR experiments were performed according to a 
previously described methodology [11]. Briefly, 
for each 25 µL reaction, PCR amplification was 
performed using 1 μL of primer/probe set, 100 ng 
to 250 ng of genomic RNA (5 µL), 12.5 μL 2X 
Reaction Mix (a buffer containing 6mM MgSO4 
and 0.4 mM each of dNTP), 0.5 μL Invitrogen 
SuperScript lll/Platinum Taq Enzyme Mix, 0.5 μL 
of RNaseOUT Recombinant Ribonuclease 
Inhibitor, and 5.5 μL of PCR-grade dH2O. The 
PCR protocol applied was50°C for 15 min (1 
cycle); 95°C for 2 min (1 cycle); 95 °C for 15 sec 
and 60 °C for 60 sec Acquisition Green channel 
for 42 cycles.  
 
BCR-ABL gene standard curve was  plotted 
based on 6 different concentrations of the BCR-
ABL gene, namely 300,000 copies/5 µL of BCR-
ABL gene, 30,000 copies/5 µL of BCR-ABL 
gene, 3,000 copies/5 µL of BCR-ABL gene, 300 
copies/5 µL of BCR-ABL gene, 30 copies/5 µL of 
BCR-ABL gene and 3 copies/5 µL of BCR-ABL 
gene. For the ABL gene standard curve, 6 
different concentrations of ABL gene were used, 
namely 300,000 copies/5 µL of ABL gene, 
30,000 copies/5 µL of ABL gene, 3,000 copies/5 
µL of ABL gene, 300 copies/5 µL of ABL gene, 
30 copies/5 µL of ABL gene and 3 copies/5 µL of 
ABL gene. The test results were expressed in 
BCR-ABL/ABL transcript ratios to allow direct 
comparison between blood cell and plasma 
values.    
Statistical analysis 
 
BCR-ABL/ABL transcript ratio was expressed as 
mean ± standard deviation (SD). Paired sample 
t-test was used to determine significant 
differences between matched plasma and cell 
samples. Differences between treatment 
response groups were analyzed using oneway 
ANOVA followed by Tukey’s post-hoc test with p 
< 0.05 considered significant. The Pearson 
bivariate correlation coefficient was utilized to 
measure the strength of relationship between 





Quality and quantity of extracted RNA    
 
As shown in Table 1, RNA extracted from plasma 
samples ranged from 5.5 ng/µL to 13.6 ng/µL, 
whereas the quantity of RNA extracted from 
blood cell samples was much higher, ranging 
from 28.6 to 176.9 ng/µL. RNA samples 
extracted from blood cell samples and plasma 
samples were pure, free from contamination 
(phenol and sodium chloride salt), with A260/280 
ratio ranging from 1.8 to 2.0 and A260/230 ratio 
greater than 2.0. The inter-assay coefficient of 
variation of real time polymerase chain reaction 
assay was 23.9 ± 2.2 %. 
 
Table 1: Quality and quantity of blood cell RNA and 
plasma RNA samples 
 
Variable Blood Cell RNA Plasma RNA 
Minimum quantity 
(ng/µL) 28.6 5.5 
Maximum quantity 
(ng/µL) 176.9 13.6 
A260/280 ratio 1.8 to 2.0 1.8 to 2.0 
A260/230 ratio >2.0 >2.0 
 
BCR-ABL/ABL transcript ratios at various 
stages of treatment response 
 
As shown in Table 2, all treatment response 
groups showed concordant results whereby 
BCR-ABL gene was detected successfully in 
both blood cell samples and plasma samples 
except for the fourth group: the CML patients 
receiving TKI therapy and who have achieved 
major molecular responses. For this particular 
treatment response group, BCR-ABL/ABL 
transcript was detected in blood cell samples 
(mean ratio was 0.1 ± 0.0 %) only, not in plasma 
samples (mean ratio was 0.0 %). In addition, 
paired t-test indicated that the mean BCR-
ABL/ABL transcript ratio was significantly higher 
(p < 0.01) in blood cell samples compared to in  
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Table 2: BCR-ABL transcripts/ABL transcripts ratio between blood cell and plasma RNA samples of CML 
patients at various treatment responses 
 
Treatment response group BCR-ABL/ABL transcript ratio (%)  
Blood cell samples Plasma samples 
Untreated newly diagnosed CML patients (n = 15) 71.2 ± 9.1a,b,c 1.5 ± 0.2 
On TKI therapy with suboptimal response (n = 35) 44.2 ± 6.9a,b,c 0.4 ± 0.2 
On TKI therapy with optimal response but have not 
achieved major molecular response (n = 55) 11.6 ± 3.3
a,d 0.5 ± 0.1 
On TKI therapy and have achieved major molecular 
response (n = 60) 0.1 ± 0.0 Undetectable 
Values represent mean ratio ± SD of 15 to 60 patient’s samples in duplicates. All inter-group comparisons 
between blood and plasma samples showed significant differences (ap < 0.01) except for patients on TKI therapy 
and have achieved major molecular response. One-way ANOVA with Tukey’s post hoc test was used for intra-
group comparisons in blood cell samples and plasma samples. Significant differences were indicated as: bp < 
0.01 compared to patients on TKI therapy with optimal response but have not achieved major molecular 
response; cp < 0.01 and dp < 0.05 compared to patients on TKI therapy and have achieved major molecular 
response. TKI: tyrosine kinase inhibitors 
 
Table 3: Correlation between BCR-ABL/ABL transcript ratio and white blood cell count in plasma and blood cells 
of CML patients for various treatment responses   
 
Treatment response group  
Mean white blood 
cell count (x 109 /L) 
Coefficient correlation between 
BCR-ABL/ABL transcript ratio 
and white blood cell count (r) 
Plasma  Blood cells 
Untreated newly diagnosed CML patients 57.40 ± 11.39 0.662** 0.800** 
On TKI therapy with suboptimal response 14.28 ± 1.70 0.036 0.889** 
On TKI therapy with optimal response but 
have not achieved major molecular response 12.25 ± 3.34 0.211 0.957** 
On TKI therapy and have achieved major 
molecular response 6.25 ± 0.28 Not applicable 0.677** 
Data represents mean ± SD and analysed using Pearson correlation coefficient test. **p < 0.01 correlation 
between plasma or blood cell samples BCR-ABL/ABL transcript ratio and white blood cell count; TKI: tyrosine 
kinase inhibitor 
 
plasma samples for all treatment response 
groups, except in CML patients who have 
achieved major molecular response. 
 
In blood cell samples, untreated newly diagnosed 
CML patients had the highest level of BCR-
ABL/ABL transcript ratios (mean ratio was 71.2 ± 
9.1 %), whereas CML patients receiving TKI 
therapy and who have achieved major molecular 
responses showed the lowest BCR-ABL/ABL 
transcript ratio (mean ratio was 0.1 ± 0.0 %). The 
one way ANOVA and Tukey’s post hoc test 
demonstrated that in blood cell samples, mean 
BCR-ABL/ABL transcript ratios of CML patients 
who have achieved major molecular responses 
were statistically different (p < 0.01) compared to 
in newly diagnosed untreated CML patients, CML 
patients with suboptimal responses (p < 0.01), 
and patients with optimal treatment responses 
but have not achieved major molecular 
responses (p < 0.05). In contrast, in plasma 
samples, there were no significant differences (p 
> 0.05) in BCR-ABL/ABL transcript ratios among 
all treatment response groups. 
 
Correlation between BCR-ABL/ABL transcript 
ratio and white blood cell count values 
 
Pearson’s bivariate correlation analysis indicated 
significant positive correlation (p < 0.01) between 
BCR-ABL/ABL transcript ratios in blood cell 
samples and their respective white blood cell 
count values (Table 3). All treatment response 
groups for blood cell samples showed strong 
positive correlation between BCR-ABL/ABL 
transcript ratios and respective white blood cell 
counts (r = 0.800 for untreated newly diagnosed 
CML patients, r = 0.889 for CML patients on TKI 
therapy and with suboptimal response, r = 0.957 
for CML patients on TKI therapy and with optimal 
response but who have not achieved major 
molecular response, and r = 0.677 for  CML 
patients on TKI therapy and who have achieved 
major molecular response). As for plasma 
samples, only the untreated newly diagnosed 
CML patients group demonstrated positive 
correlation (r = 0.662) with white blood cell count 
values. The remaining three groups 
demonstrated weak correlation with respect to 
white blood cell count values. 
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Numerous studies have shown promising results 
of using free-circulating plasma nucleic acids 
instead of peripheral blood cells for testing gene 
expression.. However, the levels of disease-
associated mutated genes are rather low in 
plasma RNA samples [12]. Similarly, our results 
revealed that though the concordance rate of 
BCR-ABL transcript detection between plasma 
RNA and blood cell RNA was 63.6 %, plasma 
RNA is far less sensitive than blood cells 
samples for the quantification of BCR-ABL 
transcripts.  
 
Compared to plasma samples, blood cell samples 
produced significantly higher (p < 0.05) levels of 
BCR-ABL transcripts at diagnosis and at different 
stages of treatment responses, and blood cell samples 
enabled sensitive detection of minimal residual 
disease. In addition, it was observed that in blood cell 
samples, there were significant differences (p < 0.05) 
of BCR-ABL/ABL transcript ratios among the four 
treatment response groups, suggesting the 
feasibility of using blood cell BCR-ABL/ABL 
transcript ratios for differentiating patients 
experiencing optimal treatment responses from 
patients experiencing suboptimal treatment 
responses. Therefore, it is evident that blood cell 
samples are a good source of RNA for the 
quantification of BCR-ABL gene expression. In 
contrast, patients with suboptimal treatment 
response could not be distinguished from 
patients with optimal response using plasma 
samples; therefore, plasma samples are not 
suitable for categorizing CML patients into 
different treatment response stages. 
 
In blood cell samples, it was observed that BCR-
ABL/ABL transcript ratios strongly correlated with 
patients’ white blood cell count values. Thus, the 
BCR-ABL transcript level in blood cells is 
indicative of the remaining tumor load in CML 
patients. As the BCR-ABL tumor load decreases 
to low or minimal levels, the patient’s white cell 
count normalizes, as observed in our results. An 
earlier study showed that there was no 
correlation between the concentration of mutated 
genes in plasma samples and tumor load. The 
reason was unclear, but it was postulated that 
plasma nucleic acids originate either from 
necrotic or from apoptotic cells and the 
underlying mechanisms need to be further 
explored [13].  
 
A subsequent comprehensive study revealed 
that macrophages play an important role in the 
generation of plasma nucleic acids. The 
concentration of nucleic acids in the plasma is 
determined by the presence or absence of 
macrophages. In the absence of macrophages, 
necrotic cells or apoptotic cells do not produce 
plasma nucleic acids. However, co-occurrence of 
macrophages and necrotic or apoptotic cells 
leads to a spontaneous increase in levels of 
plasma nucleic acids [14]. Four stages are 
involved in the generation of free-circulating 
plasma nucleic acids: 1. recognition of necrotic or 
apoptotic cells by macrophages; 2. macrophage 
engulfment of necrotic or apoptotic cells; 3. 
digestion of necrotic or apoptotic cells; and 4. 
release of nucleic acids into the plasma [15].  
 
In this study, our findings of extremely low levels 
of BCR-ABL transcripts in plasma samples of 
patients treated with TKIs are consistent with the 
hypothesis suggesting that no free-circulating 
plasma nucleic acid is produced in the absence 
of macrophages [16]. Imatinib mesylate was 
shown to inhibit the development and maturation 
of macrophages from bone marrow progenitors 
[17], as it blocks the functional capacity of 
interleukin-6 and tumor necrosis factor alpha 
resulting in the inhibition of macrophage 
maturation [18].  
 
Nilotinib, another TKI similar to imatinib 
mesylate, also blocks the signaling pathway of 
macrophage-stimulating factor receptors and 
stops the production of macrophages [19]. 
Therefore, the results herein suggest that the low 
levels of BCR-ABL/ABL transcript ratios in 
plasma samples were possibly the side effects of 
TKI drugs in eliminating monocytes or 
macrophages in CML patients. Consequently, 
inadequate number of macrophages among 
patients receiving tyrosine kinase therapy would 
delay the clear-up process of dead BCR-ABL 
positive cells, and therefore, blood cells are the 
material ideal for quantifying BCR-ABL transcript 
concentration in CML patients receiving TKI 
treatment. 
 
Limitations of the study 
 
The scope of this study was limited to CML 
patients on TKI treatment. The inference from 
this study may not be applicable to CML patients 




Plasma samples of CML patients on TKI therapy 
are not suitable for the quantification of BCR-ABL 
transcripts for treatment response monitoring. 
Blood cells are more sensitive for quantification 
assay of BCR-ABL transcripts and the values 
represent the amount of tumor load in untreated 
patients and patients on TKI therapy. 
 
Ting et al 






The authors would like to thank the Director 
General of Health Malaysia for permission to 
publish this work, as well as Dr Raudhawati 
Osman, Department of Pathology, Kuala Lumpur 
Hospital for her kind assistance. This study was 
supported by a grant from Ministry of Health, 
Malaysia. 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them.  
 
Open Access  
 
This is an Open Access article that uses a 
funding model which does not charge readers or 
their institutions for access and distributed under 
the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by 
/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 




1. Nowell PC. Discovery of the Philadelphia chromosome: a 
personal perspective. J Clin Invest 2007; 117(8): 2033-
2035. 
2. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green 
DR, Cotter TG. BCR-ABL maintains resistance of 
chronic myelogenous leukemia cells to apoptotic cell 
death. Blood 1994;  83(5): 1179-1187 
3. Masayuki O, Souichi A, Tsuyoshi I, Ken-ichiro W, Shin-ya 
T, Masaki U, Antonis SZ, Guido K, Tatsutoshi N. A novel 
mechanism for imatinib mesylate–induced cell death of 
BCR-ABL–positive human leukemic cells: caspase-
independent, necrosis-like programmed cell death 
mediated by serine protease activity. Blood 2004; 103: 
2299-2307. 
4. Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS. 
Quantitative measurement of BCR/abl transcripts using 
real-time polymerase chain reaction. Ann Oncol 2002; 
13(5): 781-788. 
5. Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, 
White HE, de Castro DG, Austin S, Awan A, Burt E, et 
al. Guidelines for the measurement of BCR-ABL1 
transcripts in chronic myeloid leukaemia. Br J Haematol 
2011; 153(2): 179-190. 
6. Park KU, Lee HE, Nam SK, Nam KH, Park DJ, Kim HH, 
Kim WH, Lee HS. The quantification of HER2 and MYC 
gene fragments in cell-free plasma as putative 
biomarkers for gastric cancer diagnosis. Clin Chem Lab 
Med 2014; 52(7): 1033-1040. 
7. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker 
P. About the possible origin and mechanism of 
circulating DNA apoptosis and active DNA release. Clin 
Chim Acta 2001; 313(1-2): 139-142. 
8. Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, 
Giles F, Cortes J, O'Brien S, Keating M, Albitar M. 
Hemizygous/homozygous and heterozygous JAK2 
mutation detected in plasma of patients with 
myeloproliferative diseases: correlation with clinical 
behaviour. Br J Haematol 2006; 134(3): 341-343. 
9. Foster CG. 1994. International ethical guidelines for 
biomedical research involving human subjects. J Med 
Ethics 1994; 20(2): 123-124. 
10. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio 
G, Apperley J, Cervantes F, Deininger M, Gratwohl A, 
Guilhot F, et al. Chronic myeloid leukemia: an update of 
concepts and management recommendations of 
European LeukemiaNet. J Clin Oncol 2009; 27(35): 
6041-6051. 
11. Ting CY, Azmi N, Makmor-Bakry M, Shamsuddin AF. 
Optimized RNA extraction for detection of BCR-ABL 
transcripts in chronic myeloid leukemia patients during 
treatment. Int J Pharm Pharm Sci 2014; 6(1): 415-418. 
12. Narita M, Saito A, Kojima A, Iwabuchi M, Satoh N, 
Uchiyama T, Yamahira A, Furukawa T, Sone H, 
Takahashi M. Quantification of BCR-ABL mRNA in 
plasma/serum of patients with chronic myelogenous 
leukemia. Int J Med Sci 2012; 9(10): 901-908. 
13. Van der VM, Pretorius PJ. The origin of circulating free 
DNA. Clin Chem 2007; 53(12): 2215. 
14. Jiang, N, Reich CF, Pisetsky DS. Role of macrophages in 
the generation of circulating blood nucleosomes from 
dead and dying cells. Blood 2003; 102(6): 2243-2250. 
15. Savill J, Fadok V. Corpse clearance defines the meaning 
of cell death. Nature 2000; 407(6805): 784-788. 
16. Choi JJ, Reich CF, Pisetsky DS. The role of macrophage 
in the in vitro generation of extracellular DNA from 
apoptotic and necrotic cells. Immunology 2005; 115(1): 
55-62. 
17. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, 
Lyons AB. Imatinib inhibits the in vitro development of 
the monocyte/macrophage lineage from normal human 
bone marrow progenitors. Leukemia 2003; 17(9): 1713-
1721. 
18. Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib 
inhibits the functional capacity of cultured human 
monocytes. Immunol Cell Biol 2005; 83(1): 48-56. 
19. Brownlow N, Russell AE, Saravanapavan H, Wiesmann 
M, Murray JM, Manley PW, Dibb NJ. Comparison of 
nilotinib and imatinib inhibition of FMS receptor 
Ting et al 
Trop J Pharm Res, March 2017; 16(3): 663  
 
signaling, macrophage production and osteoclastogenesis. Leukemia 2008; 22(3): 649-652. 
 
